THU0152 Polyautoimmunity and Familial Autoimmunity in Rheumatoid Arthritis
Authors: J.-M. Anaya, N. Molano-González, M. Rodríguez-Jiménez, J. Amaya-Amaya, J. Acosta-Ampudia, B. Reyes, R.D. Mantilla, A. Rojas-Villarraga
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Polyautoimmunity (PolyA) is defined as the presence of more than one autoimmune disease (AD) in a single patient. When three or more ADs coexist, this extreme phenotype is called multiple autoimmune syndrome (MAS). The study of the same AD in nuclear families, also referred to as familial AD, has been extensively evaluated. However, the study of familial autoimmunity [(FAI) i.e., diverse ADs in a nuclear family] has been overlooked. <h3>Objectives</h3> To evaluate factors influencing PolyA and FAI in patients with rheumatoid arthritis (RA). <h3>Methods</h3> This was a single-centre cohort study in which 955 consecutive patients (1987 ACR criteria) and their nuclear families were included. The history of 23 ADs was investigated. A comprehensive screening of autoantibodies (by IFI and ELISA) and an evaluation of affected tissue biopsies were done to validate classification criteria for each AD. The mixed-cluster methodology, based on multivariate descriptive methods (i.e., principal component and multiple correspondence analyses), was done to summarize sets of related variables with strong associations and common clinical context. Then, for each set of related variables, new cluster variables (NCV) were derived for each patient. The X2 and Fisher9s exact tests were done to establish differences between categorical variables (original and NCV) and disease (PolyA and FAI). Differences in continuous variables were evaluated by the Kruskall-Wallis test. The validity of associations was assessed by logistic regression adjusting by confounding variables. <h3>Results</h3> There were 130 (13.6%) patients who met the classification criteria for at least one other AD. A total of 161 ADs were observed in patients. The most frequent were autoimmune thyroid disease (AITD), Sjögren9s syndrome (SS), and systemic lupus erythematosus (SLE), which were present in 76 (8%), 50 (5.2%), and 24 (2.5%) cases respectively. Twenty-three patients (2.4%) presented with MAS. FAI was present in 82 (8.6%) cases in which the most frequent ADs were AITD (47%), SLE (19.5%), and SS (17.7%). Familial RA was observed in 124 (13%) cases. Main factors influencing PolyA were FAI, familial RA, and toxics (Fig.1A-1C). The effect of FAI on the risk of developing PolyA varied depending on gender. When FAI was present, the risk of developing PolyA was similar in men and women, whereas the risk of PolyA without FAI was higher in women than in men. FAI was more prevalent in those patients with a more severe disease (Fig.1D). MAS was associated with extra-articular manifestations (Fig.1E). Aggregation of ADs was confirmed (λ &gt;1) while anticipation was not observed (i.e., earlier age at onset in those patients with FAI or familial RA). <h3>Conclusions</h3> PolyA and FAI are not uncommon in RA. Both inheritable and environmental factors have an impact on PolyA. Interaction between gender and FAI was found to influence the prevalence of PolyA while FAI and PolyA, in turn, influence the severity of RA. These results may be useful in the study of gene-environment interaction. <h3>Disclosure of Interest</h3> None declared